Reason for request
Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.
Clinical Benefit
| Low |
The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease. |
Clinical Added Value
| minor |
The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease. |
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
ssGdZtrqtqL2QwRY
Listen
